CCM
XLO icon

CAAS Capital Management’s Xilio Therapeutics XLO Stock Holding History

CAAS Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,644
Closed -$592K – 956
2021
Q4 		$592K Buy
+2,644
New +$630K 0.01% 518

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

CAAS Capital Management's XLO Position: Q1 2022 in Review

CAAS Capital Management sold out of Xilio Therapeutics (XLO) in Q1 2022, closing a stake of 2,644 shares — an estimated $592K sold.

CAAS Capital Management first reported a position in XLO in Q4 2021 and held it in 1 quarter. The position peaked at $592K in Q4 2021. 41 funds tracked by Wall St. Rank hold XLO as of Q1 2022.

  • CAAS Capital Management reported no remaining Xilio Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 2,644 Xilio Therapeutics shares in Q1 2022, an estimated $592K.
  • CAAS Capital Management first reported a position in Xilio Therapeutics in Q4 2021 and held it in 1 quarter.
  • CAAS Capital Management's Xilio Therapeutics position peaked at $592K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.